I know you are relatively new to CYDY. Amazing how similar Generex and CYDY are. Both have been around a long time. Both on the OTC although GNBT was a high flyer on the NAZ before running out of funds to continue their studies. Each CEO is non medically trained but have a lot of bulldog in them. Shareholder friendliness is another common denominator. Both CEO's took over companies searching for their way. Each company has a potential product for cancer and Covid-19 although from different angles. Generex is where CYDY was back a few months ago. Struggling to pay the bills yet staying afloat. Generex has apparently applied for funding with various entities like BARDA. Not sure we know officially if CYDY has although we have comments that indicate there may be government funding coming. Generex has a deal with Chinese partners and we know CYDY is working on foreign deals. Generex is struggling to build an identity though and needs to spin off the NGIO subsidiary and take advantage of the cancer/immunological indications for AE37. CYDY was in the same boat perception wise but that is rapidly changing. The share structure is a lot better for Generex but I still think you got here at a very good time based on Covid-19 and the HIV combo BLA filing coming up. CYDY could have revenue quite soon if the FDA gets their act together in a timely manner. Generex has some revenue but desperately needs funding to really promote its non research lines of business. I have been blessed to have both companies in my portfolio although it feels like CYDY is about to bust the door down and Generex still needs time to marinate. I find it fascinating Generex thinks they can have an emergency use CV-19 vaccine by autumn. If you or someone you know needs leronlimab you know where to call!